Percutaneous ultrasound-guided chemical parathyroid ablation for treatment of primary hyperparathyroidism in dogs
Long, C.D.; Goldstein, R.E.; Hornof, W.J.; Feldman, E.C.; Nyland, T.G.
Journal of the American Veterinary Medical Association 215(2): 217-221
1999
ISSN/ISBN: 0003-1488 PMID: 10416475 Document Number: 498372
Eight dogs with primary hyperparathyroidism were used to evaluate the efficacy, feasibility, and safety of ultrasound-guided chemical ablation of parathyroid masses. Dogs were anaesthetised with propofol, and a 27-gauge needle was directed into the parathyroid mass under ultrasound guidance. Ethanol (96%) was injected into the mass until there was evidence of diffusion of fluid throughout the mass. Serum total calcium, ionized calcium, phosphorus and parathyroid hormone (PTH) concentrations were monitored daily for 5 to 7 days after the ablation and again 1, 3 and 6 months after the procedure. Follow-up ultrasonography was performed 5 days and 1 month after the ablation. One injection was required in 7 dogs, and 2 injections were required in 1 dog. Serum total and ionized calcium concentrations were within reference ranges within 24 h after treatment in 7 dogs and within 5 days in 1 dog. Serum PTH concentration decreased and serum phosphorus concentration increased within 24 h after treatment in all 8 dogs. Transient hypocalcaemia developed in 4 dogs during the first 5 days after treatment, but only 1 dog required treatment for hypocalcaemic tetany. Hypercalcaemia recurred in 1 dog 1 month after the procedure and surgical removal of the parathyroid mass was required. Other adverse effects were not reported. It is concluded that ultrasound-guided chemical ablation of parathyroid masses is a safe and effective alternative to surgery for dogs with primary hyperparathyroidism.